We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Bapineuzumab Failure Could Mean Bleak Outlook for Alzheimer’s Drugs
Bapineuzumab Failure Could Mean Bleak Outlook for Alzheimer’s Drugs
August 10, 2012
Pfizer, Johnson & Johnson (J&J) and Elan’s termination of their late-stage program for investigational Alzheimer’s drug bapineuzumab following the second failed study may not negatively impact the companies but could foreshadow a bleak outlook for the future of Alzheimer’s drug development, analysts say.